Mostafa Waleed Taha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mostafa Waleed Taha has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Shakoor Chaudhry
School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK
2 shared publications - Danielle J. C. Fenwick
Microbiology Research Department, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
2 shared publications - Emma C. L. Marrs
Microbiology Research Department, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
2 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 607
Correction: Taha et al. Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom. Microorganisms 2025, 13, 1933
- 9 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 607
Open AccessCorrection: Taha et al. Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom. Microorganisms 2025, 13, 1933
- Open Access
- 19 August 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (8) , 1933
Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom
Accurate label claims are essential for consumer trust in probiotic efficacy, yet limited datasets are available for poultry formulations marketed in the United Kingdom. We quantified and identified the viable bacteria in twelve commercial probiotics, seven for poultry and five for human use, using selective plate counts and MALDI-TOF MS. Observed colony forming units (CFU) were compared with declared values using one-sample t-tests, adopting a practical acceptance range of ±0.5 log CFU. Poultry products largely met or exceeded their labels (e.g., P5: 1.4 × 1010 CFU g−1 vs. 2 × 109 CFU g−1 declared), whereas human products delivered greater variability in both species composition and stated CFU count; one contained no detectable viable bacteria. All products deviated significantly from their label claims (p < 0.05); however, 11 of 12 met the ±0.5 log10 CFU benchmark—10 within the range and 1 above its “≥” value—leaving only one probiotic below the threshold. MALDI-TOF MS confirmed the presence of most labelled species, though Bifidobacterium bifidum was absent from one human product and Bacillus isolates were re-assigned to B. velezensis/B. amyloliquefaciens. These findings indicate robust quality assurance in UK poultry probiotics, but substantial under-delivery in the human probiotics, underscoring the need for harmonized viability standards and tighter post-market surveillance.
- 19 August 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (8) , 1933
Open AccessAssessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom
Accurate label claims are essential for consumer trust in probiotic efficacy, yet limited datasets are available for poultry formulations marketed in the United Kingdom. We quantified and identified the viable bacteria in twelve commercial probiotics, seven for poultry and five for human use, using selective plate counts and MALDI-TOF MS. Observed colony forming units (CFU) were compared with declared values using one-sample t-tests, adopting a practical acceptance range of ±0.5 log CFU. Poultry products largely met or exceeded their labels (e.g., P5: 1.4 × 1010 CFU g−1 vs. 2 × 109 CFU g−1 declared), whereas human products delivered greater variability in both species composition and stated CFU count; one contained no detectable viable bacteria. All products deviated significantly from their label claims (p < 0.05); however, 11 of 12 met the ±0.5 log10 CFU benchmark—10 within the range and 1 above its “≥” value—leaving only one probiotic below the threshold. MALDI-TOF MS confirmed the presence of most labelled species, though Bifidobacterium bifidum was absent from one human product and Bacillus isolates were re-assigned to B. velezensis/B. amyloliquefaciens. These findings indicate robust quality assurance in UK poultry probiotics, but substantial under-delivery in the human probiotics, underscoring the need for harmonized viability standards and tighter post-market surveillance.